March 14, 2019 / 11:59 AM / a month ago

BRIEF-Infinity To Initiate Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

March 14 (Reuters) - Infinity Pharmaceuticals Inc:

* INFINITY TO INITIATE MARIO-3, A PHASE 2 MULTI-ARM STUDY EVALUATING IPI-549 IN FRONT-LINE TRIPLE NEGATIVE BREAST CANCER AND RENAL CELL CANCER

* INFINITY PHARMACEUTICALS - CO ENTERS MASTER CLINICAL SUPPLY AGREEMENT WITH ROCHE TO PROVIDE ATEZOLIZUMAB FOR MARIO-3

* INFINITY PHARMACEUTICALS - MARIO-3 WILL EVALUATE IPI-549 WITH TECENTRIQ AND ABRAXANE IN FRONT-LINE TRIPLE NEGATIVE BREAST CANCER

* INFINITY PHARMACEUTICALS - MARIO-3 WILL ALSO EVALUATE IPI-549 WITH TECENTRIQ AND AVASTIN IN FRONT-LINE RENAL CELL CANCER

* INFINITY PHARMACEUTICALS - UNDER TERMS, ROCHE WILL SUPPLY ATEZOLIZUMAB TO INFINITY FOR USE IN MARIO-3, A PHASE 2 MULTI-ARM COMBINATION COHORT STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below